Podcast UnWRapped - banner advert
Huntleigh Academy - Demystifying Doppler - banner advert
Convatec and ConvaNiox

ConvaNioxTM provides a best-in-class, transformative solution for patients with diabetic foot ulcers (DFU).1

ConvaNiox product

ConvaNiox is a two-part, multilayered, multimodal wound dressing that creates an optimised wound healing environment to increase the probability of healing of diabetic foot ulcers (DFUs) by combining an advanced dressing technology with an effective antimicrobial and antibiofilm agent, nitric oxide (NO).2

The combined effects of each feature of the ConvaNiox dressing composition addresses multiple fundamental challenges of hard-to-heal wounds:

Optimised wound healing environment to increase the probability of healing of diabetic foot ulcers2

  • Creates and maintains a moist wound environment, donating moisture (when required), regulating wound moisture balance to support autolytic debridement.
  • Draws wound exudate and its components into the dressing by creating a high osmotic gradient which stimulates fluid flow into the dressing.
  • Neutralises the alkaline pH of chronic wound exudate within the dressing, lowering pH to a more acidic level which is inhibitory towards microorganisms and favourable to healing.

Antimicrobial and antibiofilm protection2

  • Generates nitric oxide, an effective antimicrobial and antibiofilm agent, exerting a combination of actions within the dressing to provide antimicrobial protection, and disrupt, kill and prevent biofilm formation, including antibiotic-resistant and single species biofilms, polymicrobial biofilms, and fungal biofilms.

Enhanced dressing capability2

  • The absorbent protective layer provides an effective barrier to external bacterial penetration.
  • Continually absorbs and retains wound fluid, then evaporates excess moisture due to its high moisture vapour transmission rate.
photo
ConvaNiox

Powered by Nitric Oxide

When managing DFU’s, big losses can start small

ConvaNiox Image

The above diagram is an artistic illustration of the device.

icon

BARRIER TO BACTERIAL PENETRATION²

icon

EVAPORATION OF EXCESS MOISTURE²

icon

ABSORPTION OF WOUND EXUDATE²

icon

LOWERS pH OF ABSORBED WOUND EXUDATE²

icon

HIGH OSMOTIC GRADIENT FOR FLUID FLOW²

icon

REGULATES MOISTURE BALANCE²

icon

NITRIC OXIDE FOR ANTIMICROBIAL AND ANTIBIOFILM PROTECTION²

CONVATEC

Convatec is a global medical products and technologies company focused on therapies for the management of chronic conditions, leading in advanced wound care, ostomy care, continence care, and infusion care

To learn more about Convatec, please click the button below to visit their website:

Interested in ConvaNiox™?
Please fill in the form below to contact Convatec.

Email(Required)

Available ConvaNiox Resources

Introducing ConvaNio

ConvaNiox™ Webinar

Introducing ConvaNiox – A Unique Nitric Oxide Multimodal Dressing system. On demand webinar with Toby Daff, Clinical Podiatrist at Goulburn Valley Health. 

Revolutionary healing with nitric oxide technology in hard-to-heal wounds

ConvaNiox™ Seminar

Dr Chris Manu, Consultant Diabetologist at King’s College Hospital, London, talks about the revolutionary healing with nitric oxide technology in hard-to-heal wounds.

interview

ConvaNiox™

In this short interview, Saskia, Director of Podiatry for South Western Sydney Local Health District, shares her perspective on ConvaNiox™.

brochure

Brochure

Discover ConvaNiox – Read more about diabetic foot ulcers, the challenges of biofilm and the innovative technology that sets ConvaNiox apart

One-Pager RCT AU

RCT one page summary

Multicenter, randomized controlled, observer-blinded study of a nitric oxide generating treatment in foot ulcers of patients with diabetes—ProNOx1 study

ConvaNiox CEA

Cost-Effectiveness summary

Cost-effectiveness of a nitric oxide generating medical device in managing hard-to-heal diabetic foot ulcers

References:

1. Edmonds ME, et al. Multicenter, randomized controlled, observer-blinded study of a nitric oxide generating treatment in foot ulcers of patients with diabetes-ProNOx1 study. Wound Repair Regen. 2018;26(2):228-237.

2. ConvaNiox Claims summary. RPT-088112, 2025, Data on file, Convatec Inc.